Angelini Pharma, Inc.

▎药明康德内容团队编辑 据创鉴汇不完全统计，上周（9月23日至9月29日）全球大健康领域共披露融资事件27起，总额近60亿元。按照金额划分，亿元及以上融资12起。按照已披露的融资轮次划分，早期融资（B轮以前）13起，中后期融资（B轮及以后）10起。生物医药领域共8家公司获融资，涉及药物类型包括疫苗、抗体、基因疗法、小分子药物等。 #01  BioAge Labs完成IPO 关键词：小分子药物 最新融资：1.98亿美元IPO 9月26日，BioAge Labs在纳斯达克上市，募资1.98亿美元，该融资所得将用于推动其减肥管线的临床试验。BioAge Labs是一家专注于肥胖症治疗的临床阶段生物技术公司。BioAge Labs的主要候选药物Azelaprag是一种口服小分子药物，属于Apelin受体激动剂。该产品正在与礼来GLP-1/GI受体激动剂Tizepatide联合开展减肥2期临床试验，它还将于明年上半年与诺和诺德减肥产品Wegovy联合进入2期试验。 #02 Vicebio完成1亿美元B轮融资 关键词：疫苗 最新融资：1亿美元B轮 本轮投资机构：Avoro Ventures、Goldman Sachs Alternatives、Medicxi、TCG Crossover、UniQuest等 9月23日，Vicebio宣布完成1亿美元的B轮融资，获得的资金将用于推动其双价疫苗VXB-241的1期临床试验，该疫苗靶向呼吸道合胞病毒（RSV）和人偏肺病毒（hMPV）。这笔资金还将支持Vicebio多价疫苗管线的加速开发，包括VXB-251，这是一种靶向RSV、hMPV和副流感病毒3型（PIV3）的三价疫苗。Vicebio致力于开发针对呼吸道病毒的下一代疫苗，采用其专有的分子钳技术（molecular clamp）。该技术由昆士兰大学发现，能够独特地稳定病毒糖蛋白处于高度免疫原性的融合前构象，这对于引发强有力的保护性免疫反应至关重要。 #03 Genespire完成4660万欧元B轮融资 关键词：基因疗法 最新融资：4660万欧元B轮 本轮投资机构：CDP Venture Capital、Sofinnova Partners、XGen Ventures 9月25日，Genespire宣布完成4660万欧元B轮融资，获得资金将支持该公司的核心候选产品GENE202的开发，直至进入治疗甲基丙二酸血症（MMA）的1/2期临床试验。此外还将加强公司产品管线，促进针对多种其他遗传疾病候选疗法的发现和临床前研究。GENE202是一种现货型基因疗法，利用了该公司的免疫屏蔽慢病毒载体（ISLV）平台，设计为可静脉注射。ISLV的作用机制使Genespire的治疗方法特别适用于当前面临最紧迫未满足医疗需求的遗传病儿童患者，同时也能惠及成人患者。 #04 天辰生物完成近亿元B2轮融资 关键词：抗体 最新融资：近亿元B2轮 本轮投资机构：启明创投 9月24日，天辰生物宣布成功完成近亿元B2轮融资。通过本轮融资，天辰生物将推进核心项目在中国的临床研究，加速产品上市进程，并助力国际布局。天辰生物成立于2020年，是一家致力于过敏和补体领域大分子创新药开发的中国生物技术公司。今年6月，天辰生物进展较快的新一代抗IgE抗体药物LP-003注射液，启动治疗季节性过敏性鼻炎患者的3期临床试验。此外，LP-005是潜在“first-in-class”C5与C3补体双功能抗体，已启动阵发性睡眠性血红蛋白尿症（PNH）的2期临床试验。根据天辰生物官网，该公司临床前在研管线还包括AAV介导的补体抑制剂LP-008项目，拟开发治疗年龄相关性黄斑变性（AMD）等。 #05 Aptadir Therapeutics完成160万美元pre-种子轮融资 关键词：寡核苷酸 最新融资：160万美元pre-种子轮 本轮投资机构：Angelini Ventures、Evotec、EXTEND 9月24日，Aptadir Therapeutics宣布正式成立，致力于开发基于RNA的创新疗法，治疗难治性癌症和遗传疾病。Aptadir从EXTEND技术转移生物技术中心获取了160万美元的pre-种子资金，用以优化其主要资产Aptadir Ce-49。该药物正在开发用于治疗骨髓增生异常综合征，目标是在2025年底进入临床开发阶段。该公司的技术平台基于一种能够与DNA甲基转移酶（DNMTs）相互作用的RNA分子。这些RNA分子能够精准地阻断特定基因的异常DNA甲基化，重新激活先前由于高度甲基化而不表达的基因。某些基因高度甲基化是癌症和遗传性疾病的一个关键特征。通过重新激活特定基因，有望针对一些疾病的根本原因进行治疗，比如骨髓增生异常综合征（MDS）和脆性X综合征。 读者们请星标⭐创鉴汇，第一时间收到推送 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。 版权说明：本文由药明康德内容团队根据公开资料整理编辑，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转发/复制至其他平台。转发授权请在「创鉴汇」微信公众号留言联系我们。 更多数据内容推荐 点击“在看”，分享创鉴汇健康新动态

With a career dedicated to delivering firsts in medicine and innovating to find new ways to treat patients, McKerracher’s expertise will help Genialis commercialize first-in-class biomarkers. BOSTON--(BUSINESS WIRE)-- Genialis, the RNA-biomarker company, today announced the appointment of Krista McKerracher as Chairperson of the Board of Directors. McKerracher is a seasoned biopharmaceutical leader passionate about bringing new medicines to patients with life-threatening diseases. Her background includes almost three decades at Johnson & Johnson and Novartis Oncology, where she held senior commercial and senior R&D leadership roles and launched several first-in-class drugs in the hematology/oncology space. McKerracher rounded out her drug development career at CRISPR Therapeutics, where she led the team that brought the first CRISPR Cas9 ex-vivo gene editing product to the clinic (HbF edited stem cells for hemoglobinopathies.) This press release features multimedia. View the full release here: Genialis Introduces Krista McKerracher as Chairperson of the Board. Pictured from left to right is the Genialis Board of Directors: Franck Brichory, Debiopharm Innovation Fund (observer); Cédric Odje, Debiopharm Innovation Fund; Krista McKerracher, Fig Advisory; Rafael Rosengarten, PhD, CEO & co-founder, Genialis; Miha Štajdohar, PhD, CTO & co-founder, Genialis; Elia Stupka, PhD, Angelini Ventures; Ita Lu, Taiwania Capital; Paoyen Lai, Taiwania Capital (observer) (Photo: Business Wire) McKerracher joins Cedric Odje, representing Debiopharm Innovation Fund; Ita Lu of Taiwania Capital; independent director Elia Stupka; and Genialis co-founders Rafael Rosengarten, Ph.D. (chief executive officer) and Miha Štajdohar, Ph.D. (chief technology officer) on the board. “Throughout my career, I’ve worked on a lot of firsts. Genialis has a promising opportunity to be the first to harness the vast amount of data contained in a small tumor sample and use that to bring reality to truly personalized medicine – delivering the right drug for the right patient at the right time,” said McKerracher. “When I was diagnosed with cancer in 2015, tumor sequencing was still brand new, and despite working in the field, many of my colleagues were skeptical about the value of sequencing for my tumor type because links to specific mutations were not well understood. With the Genialis approach to RNA-based biomarkers, I believe that in the future, all patients will have their tumors sequenced as standard of care. Genialis is on the leading edge of precision medicine, driving innovation and hope for patients globally.” Ms. McKerracher is an experienced public company board member known for bringing a solid commercial orientation to the drug development process. McKerracher graduated from the University of Waterloo (BSc. Hon. Applied Health Sciences) and earned an MBA from York University. “When we started our search for a board chair, we focused on finding someone who embraced our company value of ‘people first’ and committed to improving outcomes for patients globally,” said Dr. Rosengarten. “Krista brings the perspective of someone who has overseen the entire drug development life cycle on a global scale for some of the preeminent pharma companies, helping Genialis direct its biomarker algorithms to the most critical pain points in the process.” Genialis recently announced a breakthrough development in its predictive biomarker for KRAS inhibitor therapies and is currently enrolling select participants in its early access program. Genialis krasID is a new Artificial Intelligence classifier that accurately predicts response and clinical benefit to KRAS inhibitors across preclinical, clinical, and real-world settings. Most biomarkers in the KRAS space measure only KRAS mutation status, which may be necessary to receive the drug but is insufficient to predict or monitor response or to inform combinations or subsequent therapeutic interventions. By using high-dimensional gene expression data, Genialis krasID captures underlying biological complexity unique to each individual patient. Over 50 biopharma companies are currently developing more than 70 different KRAS-targeted drugs across over 12 disease indications. The total KRAS therapy market today is estimated at approximately $240 million, with a compound annual growth rate of 36% to reach $10 billion by 2032. Meanwhile, available diagnostics to support KRAS-targeted patient care are limited to mutation-based tests. Genialis is participating in the Festival of Genomics & BioData this week in Boston. Dr. Rosengarten will give a talk in the Live Lounge titled, “Genialis™ krasID: Biology-Driven Machine Learning to Personalize KRAS Inhibitor Therapy” on Wednesday, June 12, 2024, from 12:10 PM to 12:40 PM EDT. To schedule a meeting at the Frontline Genomcis event, or learn more about Genialis biomarker programs, please visit or email biomarkers@genialis.com About Genialis Genialis, the RNA biomarker company, is creating a world where healthcare delivers the best possible outcomes for patients, their families, and their communities. Genialis develops and validates clinically actionable biomarkers informed by the world’s most ethnographically diverse cancer data sets to better predict patient responses and guide treatment decisions for targeted inhibitors, immunotherapies, and other emerging therapeutic classes. Genialis is trusted by pharma and diagnostics partners, and together, we are transforming medicine through data. For more information, please visit . View source version on businesswire.com: Contacts Source: Genialis Smart Multimedia Gallery Photo Genialis Introduces Krista McKerracher as Chairperson of the Board. Pictured from left to right is the Genialis Board of Directors: Franck Brichory, Debiopharm Innovation Fund (observer); Cédric Odje, Debiopharm Innovation Fund; Krista McKerracher, Fig Advisory; Rafael Rosengarten, PhD, CEO & co-founder, Genialis; Miha Štajdohar, PhD, CTO & co-founder, Genialis; Elia Stupka, PhD, Angelini Ventures; Ita Lu, Taiwania Capital; Paoyen Lai, Taiwania Capital (observer) (Photo: Business Wire) Logo View this news release and multimedia online at:

The medicines are indicated for usage as a second line treatment option for acute pain and primary dysmenorrhea. Credit: Kmpzzz / Shutterstock.com. Helsinn Group has renewed a distribution and licence agreement with Angelini Pharma for the commercialisation of AULIN and MESULID (Nimesulide) to treat acute short-term pain in six European countries. The territories covered under the renewed deal include Bulgaria, the Czech Republic, Hungary, Poland, Romania and the Slovak Republic. The non-selective, non-steroidal anti-inflammatory drugs AULIN and MESULID are offered on prescription as an oral tablet and granules for oral suspension. They are indicated for usage as a second-line treatment option for acute pain and primary dysmenorrhea. AULIN gel, also marketed under the brand name AulinDol, is available on prescription or over the counter. See Also: FDA accepts Sanofi’s Sarclisa sBLA for priority review South Korea’s MFDS approves Eisai-Biogen’s LEQEMBI for Alzheimer’s It is intended to provide symptomatic relief of pain linked to sprains and acute traumatic tendinitis. Helsinn Group CEO Dr Melanie Rolli stated: “We are pleased to have signed this agreement with Angelini and honoured to maintain our ongoing collaboration. “Our long-standing partnership with Angelini exemplifies how Helsinn fosters relationships and alliances to deliver essential products to patients. We appreciate their extensive reach in these countries, which enables patient access to this much-needed treatment.” Angelini Pharma International Operations executive vice-president Erik Lommerde stated: “We are delighted to renew our partnership with Helsinn. “This collaboration is built on a foundation of mutual trust, highlighted by our shared commitment to professional excellence, in-depth product knowledge, and high-quality service. This alliance is crucial for both parties and represents a strong business relationship.” In May 2023, Angelini Pharma and JCR Pharmaceuticals signed a global development and commercialisation agreement focused on developing novel biologic therapies. This collaboration utilises J-Brain Cargo technology to address epilepsy. JCR Pharmaceuticals received research expense reimbursements, upfront payments and milestone payments of $505.5m, in addition to tiered royalties on net product sales post-approval.